A study examined the effects of glucagon-like peptide-1 receptor agonists on alcohol consumption and weight loss in obese patients. The research revealed that treatment with these medications led to a significant reduction in alcohol intake and also facilitated weight loss, indicating a potential dual benefit. Although the study had limitations, it provided real-world evidence supporting the drugs' role in addressing both obesity and alcohol use.

Source: Diabetes, Obesity and Metabolism